Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients:: GEICAM 2002-03 Study

被引：0
|
作者：
Estévez, LG
Adrover, E
Barnadas, A
Cuevas, JM
Seguí, MA
机构：
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S229 / S229
页数：1
相关论文
共 50 条
  • [1] Doxorubicin and cyclophosphamide followed by weekly docetaxel (AC-T) as neoadjuvant chemotherapy in operable breast cancer patients: Interim results from the 2002-03 GEICAM study
    Estevez, Laura G.
    Adrover, Encarna
    Barnandas, Agusti
    Cuevas, Jose M.
    Segui, Miguel A.
    ANNALS OF ONCOLOGY, 2004, 15 : 65 - 66
  • [2] Phase II study of AC (doxorubicin and cyclophosphamide) followed by weekly paclitaxel as neoadjuvant chemotherapy in operable patients with primary breast cancer
    Iwase, S.
    Yamamoto, D.
    Kitamura, K.
    Odagiri, H.
    Teramoto, S.
    Ohtani, S.
    Doi, T.
    Kinebuchi, K.
    Kuroda, Y.
    Nagumo, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
    Estevez, Laura G.
    Fortes, Jose Luis
    Adrover, Encarna
    Peiro, Gloria
    Margeli, Mireia
    Castella, Eva
    Cuevas, Jose Miguel
    Bernet, Laia
    Segui, Miguel Angel
    Andreu, Xavier
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2009, 11 (01): : 54 - 59
  • [4] Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
    Laura G. Estevez
    José Luis Fortes
    Encarna Adrover
    Gloria Peiró
    Mireia Margelí
    Eva Castellá
    José Miguel Cuevas
    Laia Bernet
    Miguel Angel Segui
    Xavier Andreu
    Clinical and Translational Oncology, 2009, 11 : 54 - 59
  • [5] A phase II study to evaluate the feasibility of bi-weekly docetaxel followed by bi-weekly doxorubicin and cyclophosphamide as adjuvant therapy for operable breast cancer (T-AC).
    Lambert-Falls, R
    Ackerman, M
    Jones, GT
    Smith, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 88S - 88S
  • [6] PHASE II STUDY OF DOCETAXEL AND DOXORUBICIN COMBINATION AS NEOADJUVANT CHEMOTHERAPY IN OPERABLE BREAST CANCER PATIENTS
    Uddin, D.
    Hannan, A. A.
    Ahmed, I.
    ANNALS OF ONCOLOGY, 2010, 21 : 92 - 92
  • [7] Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
    Gradishar, WJ
    Wedam, SB
    Jahanzeb, M
    Erban, J
    Limentani, SA
    Tsai, KT
    Olsen, SR
    Swain, SM
    ANNALS OF ONCOLOGY, 2005, 16 (08) : 1297 - 1304
  • [8] Docetaxel Followed by Fluorouracil/Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy for Patients with Primary Breast Cancer
    Iwata, Hiroji
    Sato, Nobuaki
    Masuda, Norikazu
    Nakamura, Seigo
    Yamamoto, Naohito
    Kuroi, Katsumasa
    Kurosumi, Masafumi
    Tsuda, Hitoshi
    Akiyama, Futoshi
    Ohashi, Yasuo
    Toi, Masakazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (07) : 867 - 875
  • [9] Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer
    Ganem, G
    Tubiana-Hulin, M
    Fumoleau, P
    Combe, M
    Misset, JL
    Vannetzel, JM
    Bachelot, T
    De Ybarlucea, LR
    Lotz, V
    Bendahmane, B
    Dieras, V
    ANNALS OF ONCOLOGY, 2003, 14 (11) : 1623 - 1628
  • [10] Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
    Hong, Woo Sung
    Jeon, Ja Young
    Kang, Seok Yun
    Jung, Yong Sik
    Kim, Ji Young
    Ahn, Mi Sun
    Kang, Doo Kyoung
    Kim, Tae Hee
    Yim, Hyun Ee
    An, Young-Sil
    Park, Rae Woong
    Kim, Ku Sang
    JOURNAL OF THE KOREAN SURGICAL SOCIETY, 2013, 85 (01): : 7 - 14
12345